Effects of Ticlopidine (Panaldine) on patients with vertigo and equilibrium dysfunction.

概要

論文の詳細を見る
ADP-induced platelet aggregation was studied in 442 patients with vertigo and equilibrium dysfunction and enhanced platelet aggregation was noted in most of the patients. This result suggested that higher platelet aggregation was "a risk factor" for vertiginous disease.Therefore, we administered Ticlopidine (Panaldine), a suppressant of platelet activity, to 33 patients and evaluated its clinical effectiveness on their subjective symptoms and objective findings.The following results were obtained.1) Ticlopidine was effective in 24 of the 33 cases (72.7%).2) Ticlopidine reduced vestibular subjective symptoms, but its effect on cochlear symptoms was limited.3) Among the objective findings, Ticlopidine was effective on nystagmus (gaze, positional and positioning nystagmus), but less effective on the caloric nystagmus test, OKN-test, ETT and Schellong's test. Hearing was not improved.4) Platelet aggregation was markedly suppressed in 32 of the 33 cases (97%).5) As to the side effects, only one patient complained of abdominal discomfort, but this was not severe.These results suggest that Ticlopidine is useful in the treatment of vertigo and equilibrium dysfunction.